精神藥物市場規模、佔有率、成長分析（按藥物類型、應用、藥物類別、疾病、分銷管道和地區）－2025-2032 年產業預測

預計 2023 年全球精神藥物市場價值將達到 238 億美元，從 2024 年的 248 億美元成長到 2032 年的 344.7 億美元，預測期內（2025-2032 年）的複合年成長率為 4.2%。

全球精神藥物市場正經歷顯著成長，這得益於人們對心理健康問題的認知不斷提高以及焦慮症和憂鬱症盛行率的上升。醫療保健可近性的改善以及藥物研發技術的進步，都促進了這一成長。此外，精神病治療的接受度不斷提高以及政府旨在加強心理健康計畫的扶持政策，也進一步推動了市場需求。新興經濟體的發展和可支配收入水準的提高也推動了這一趨勢，從而推動了全球精神藥物的使用增加。因此，這些因素共同凸顯了不斷變化的市場格局和市場潛力，凸顯了在成熟市場和新興市場中解決心理健康問題的重要性。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

精神藥物市場規模（按藥物類型和複合年成長率）（2025-2032）

• 市場概況
• Aripiprazole
• 布昔吡唑
• Olanzapine
• Peri-Peri酸哌利酮
• 氯氮平
• Quetiapine
• 氯丙嗪
• Risperidone
• 帕羅西汀
• 硫利達嗪
• 氟伏沙明
• 其他藥物類型

精神藥物市場規模：依應用和複合年成長率（2025-2032）

• 市場概況
• 抗精神病藥物
• 抗焦慮
• 情緒穩定劑
• 抗憂鬱症
• 興奮劑
• 催眠藥
• 抗癲癇藥物
• 其他用途

精神藥物市場規模：依治療層級及複合年成長率（2025-2032）

• 市場概況
• 第一代
• 第二代
• 第三代

精神藥物市場規模：依疾病及複合年成長率（2025-2032）

• 市場概況
• 思覺失調症
• 躁鬱症
• 單相憂鬱症
• 失智
• 其他疾病

精神藥物市場規模：依分銷管道及複合年成長率（2025-2032）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

精神藥物市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比比較（2022-2024 年）

主要企業簡介

• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• AstraZeneca Plc（UK）
• Otsuka Holdings Co., Ltd.（Japan）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• GlaxoSmithKline（GSK）（UK）
• Bristol-Myers Squibb（BMS）（USA）
• H. Lundbeck A/S（Denmark）
• Janssen Pharmaceuticals（J&J Subsidiary）（USA）
• Viatris Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Merck & Co., Inc.（USA）
• Roche Holding AG（Switzerland）
• Jazz Pharmaceuticals plc（Ireland）
• Neurocrine Biosciences, Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Biogen Inc.（USA）

結論和建議

Global Psychotropic Drugs Market size was valued at USD 23.8 billion in 2023 and is poised to grow from USD 24.8 billion in 2024 to USD 34.47 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global psychotropic drugs market is experiencing significant growth, propelled by a heightened awareness of mental health issues and rising incidences of anxiety and depression. Enhanced healthcare accessibility is contributing to this expansion, alongside advancements in drug development technologies. Furthermore, the increasing acceptance of psychiatric treatments and supportive government initiatives aimed at bolstering mental health programs are further driving market demand. The trend is also supported by emerging economies and a rise in discretionary income levels, facilitating greater utilization of psychotropic medications globally. As a result, these factors collectively underscore the evolving landscape and potential of the psychotropic drugs market, highlighting the importance of addressing mental health in both established and developing markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychotropic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychotropic Drugs Market Segments Analysis

Global Psychotropic Drugs Market is segmented by Drug Type, Application, Therapeutic Class, Disease, Distribution Channel and region. Based on Drug Type, the market is segmented into Aripiprazole, Brexipiprazole, Olanzapine, Peliperidone Palmitate, Clozapine, Quetiapine, Chlorpromazine, Risperidone, Paroxetine, Thioridazine, Fluvoxamine and Other Drug Types. Based on Application, the market is segmented into Anti-Psychotics, Anti-Anxiety, Mood Stabilizers, Antidepressants, Stimulants, Hypnotics, Antiepileptic Drugs and Other Applications. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is experiencing growth driven by increased awareness surrounding mental health, bolstered by public information campaigns and support from celebrity advocates that have normalized mental health treatment. This heightened awareness has led to more frequent diagnoses of mental illnesses. Furthermore, supportive government initiatives and strategic workplace wellness programs have enhanced the accessibility and prescription rates of various psychotropic medications, such as antidepressants, anxiolytics, and antipsychotics, particularly among urban populations facing high levels of stress. The combination of these factors is fostering a greater acceptance and utilization of mental health treatments on a global scale.

Restraints in the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market faces significant constraints due to the rigorous safety and efficacy evaluations conducted by regulatory authorities, which prolong the time to market for new products. The complexity of conducting clinical trials for mental health disorders, particularly given the subjective nature of diagnoses, contributes to elevated development costs. Furthermore, the necessity for stringent post-marketing surveillance, such as monitoring for potential suicide risks associated with antidepressants, compounds these financial challenges, particularly for smaller pharmaceutical companies that may lack the resources to manage such burdens. These factors collectively hinder innovation and timely market entry in this sector.

Market Trends of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is increasingly shifting towards precision medicine, emphasizing personalized treatment options that utilize genetic testing and biomarker-driven approaches. Advancements in pharmacogenomics and the identification of biomarkers, such as BDNF levels and CYP450 enzyme profiles, are enhancing the ability to tailor psychotropic medications to individual patient needs, thereby reducing the trial-and-error approach traditionally associated with prescribing. This trend is further propelled by innovative companies developing psychedelic-based therapies, which are garnering significant venture capital investments and fostering partnerships within the healthcare ecosystem, ultimately driving growth and transformation in the psychotropic drugs sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Psychotropic Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Aripiprazole
• Brexipiprazole
• Olanzapine
• Peliperidone Palmitate
• Clozapine
• Quetiapine
• Chlorpromazine
• Risperidone
• Paroxetine
• Thioridazine
• Fluvoxamine
• Other Drug Types

Global Psychotropic Drugs Market Size by Application & CAGR (2025-2032)

• Market Overview
• Anti-Psychotics
• Anti-Anxiety
• Mood Stabilizers
• Antidepressants
• Stimulants
• Hypnotics
• Antiepileptic Drugs
• Other Applications

Global Psychotropic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• First Generation
• Second Generation
• Third Generation

Global Psychotropic Drugs Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

Global Psychotropic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Psychotropic Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (J&J Subsidiary) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations